Loveytan
2021-03-01
Lol
Merck KGaA inks xevinapant licensing deal in head, neck cancer
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
5
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":362338930,"tweetId":"362338930","gmtCreate":1614595092020,"gmtModify":1703478607464,"author":{"id":3572158983231416,"idStr":"3572158983231416","authorId":3572158983231416,"authorIdStr":"3572158983231416","name":"Loveytan","avatar":"https://static.tigerbbs.com/34c80695455223ae87f77cb5adb10f85","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":21,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Lol</p></body></html>","htmlText":"<html><head></head><body><p>Lol</p></body></html>","text":"Lol","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/362338930","repostId":1188492560,"repostType":4,"repost":{"id":"1188492560","kind":"news","pubTimestamp":1614592156,"share":"https://www.laohu8.com/m/news/1188492560?lang=&edition=full","pubTime":"2021-03-01 17:49","market":"us","language":"en","title":"Merck KGaA inks xevinapant licensing deal in head, neck cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1188492560","media":"Seekingalpha","summary":"Merck KGaA(OTCPK:MKGAF) announcesa worldwide in-licensing agreement with Debiopharm, Switzerland, fo","content":"<p>Merck KGaA(OTCPK:MKGAF) announcesa worldwide in-licensing agreement with Debiopharm, Switzerland, for the development and commercialization of xevinapant (Debio 1143).</p>\n<p>Under the terms of agreement, Merck KGaA, gains exclusive rights to develop and commercialize xevinapant worldwide, including in the U.S.</p>\n<p>Debiopharm will receive €188M in upfront payments and up to €710M in milestones, as well as royalty payments.</p>\n<p>Merck KGaA will co-fund with Debiopharm the ongoing Phase III TrilynX study, to evaluate the efficacy and safety of xevinapant vs. placebo when added to definitive chemoradiotherapy (CRT) in cisplatin-eligible patients with high-risk locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).</p>\n<p>Merck KGaA will also initiate a second global Phase III study to evaluate xevinapant in patients with LA SCCHN who are unable to tolerate high-dose cisplatin in combination with radiotherapy.</p>\n<p>The agreement also includes development rights for preclinical follow-on compounds to xevinapant.</p>\n<p>The transaction is expected to close in early Q2.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck KGaA inks xevinapant licensing deal in head, neck cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck KGaA inks xevinapant licensing deal in head, neck cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-01 17:49 GMT+8 <a href=https://seekingalpha.com/news/3667428-merck-kgaa-inks-xevinapant-licensing-deal-in-head-neck-cancer><strong>Seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Merck KGaA(OTCPK:MKGAF) announcesa worldwide in-licensing agreement with Debiopharm, Switzerland, for the development and commercialization of xevinapant (Debio 1143).\nUnder the terms of agreement, ...</p>\n\n<a href=\"https://seekingalpha.com/news/3667428-merck-kgaa-inks-xevinapant-licensing-deal-in-head-neck-cancer\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MKGAF":"Merck KGaA","MKKGY":"Merck KGaA"},"source_url":"https://seekingalpha.com/news/3667428-merck-kgaa-inks-xevinapant-licensing-deal-in-head-neck-cancer","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1188492560","content_text":"Merck KGaA(OTCPK:MKGAF) announcesa worldwide in-licensing agreement with Debiopharm, Switzerland, for the development and commercialization of xevinapant (Debio 1143).\nUnder the terms of agreement, Merck KGaA, gains exclusive rights to develop and commercialize xevinapant worldwide, including in the U.S.\nDebiopharm will receive €188M in upfront payments and up to €710M in milestones, as well as royalty payments.\nMerck KGaA will co-fund with Debiopharm the ongoing Phase III TrilynX study, to evaluate the efficacy and safety of xevinapant vs. placebo when added to definitive chemoradiotherapy (CRT) in cisplatin-eligible patients with high-risk locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).\nMerck KGaA will also initiate a second global Phase III study to evaluate xevinapant in patients with LA SCCHN who are unable to tolerate high-dose cisplatin in combination with radiotherapy.\nThe agreement also includes development rights for preclinical follow-on compounds to xevinapant.\nThe transaction is expected to close in early Q2.","news_type":1},"isVote":1,"tweetType":1,"viewCount":116,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/362338930"}
精彩评论